Masupirdine
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
1
Recruiting
1
Completed
1
Sites
114
Countries
4
Endpoints
12
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 12 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 10 of 12 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
2
2
2
2
2
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT02580305SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study | Donepezil, Masupirdine, Memantine Alzheimer’s disease | Alzheimer's disease | Ph 2 | Completed | 71 | Nov 2019 | 3 | results |
| NCT05397639Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type | Masupirdine Alzheimer’s disease | Alzheimer's disease | Ph 3 | Recruiting | 44 | Dec 2026 | - | |
| SUVN-502Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease | Masupirdine Alzheimer’s disease | Age 50-85 | Not applicable | Unknown | 0 | - | - |
Showing 1-3 of 3 trials